The immune landscape of these tumors shows increased intratumoral myeloid and T cells (152), while loss of LKB1 in KRAS-mutated NSCLC results in higher levels of CXCL7, G-CSF, and IL-6, which promote neutrophil recruitment and macrophage activation and thereby suppress T cell activity (153). Here, KRAS is linked to non-small cell lung carcinoma.